Microbiologics Expands with SensID Acquisition
Deal News | Nov 06, 2024 | PR Newswire Cision Microbiologics
Microbiologics, a global leader in the field of biotechnology, has announced its acquisition of SensID, a prominent provider of reference materials and quality controls for molecular diagnostics, with a particular emphasis on oncology and precision medicine. This acquisition marks a significant milestone in Microbiologics' mission to advance a safer and healthier world by extending its expertise into oncology and precision medicine while maintaining its leadership in infectious disease diagnostics. The collaboration between Microbiologics and SensID will enable an expanded portfolio of solutions for developers of diagnostic technologies, ultimately improving global patient care. The acquisition signals Microbiologics' first international expansion, with Rostock, Germany serving as its inaugural site outside the United States. Commenting on this milestone, Kristen Knox, CEO of Microbiologics, emphasized the commitment to advancing the future of diagnostics and improving the lives of patients and healthcare professionals worldwide. SensID, renowned for precision and innovation, will continue to contribute its expertise in providing intensively characterized reference materials essential for the development, validation, and quality control of molecular diagnostic tests. The partnership aligns closely in their mission and values, enhancing the trajectory of innovation in diagnostic test development.
Sectors
- Biotechnology
- Healthcare & Diagnostics
- Private Equity
Geography
- United States – Microbiologics is headquartered in Saint Cloud, Minnesota, indicating the US as a primary geographical context.
- Germany – SensID is based in Rostock, Germany, and the acquisition expands Microbiologics' footprint into this new international location.
Industry
- Biotechnology – Microbiologics and SensID operate within the biotechnology industry, focusing on providing advanced diagnostic solutions and quality control materials for infectious diseases and oncology.
- Healthcare & Diagnostics – The acquisition focuses on improving diagnostic capabilities, particularly in the area of molecular diagnostics related to oncology and infectious diseases.
- Private Equity – Granite Partners, a private investment and holding company, is involved in supporting Microbiologics' acquisition of SensID.
Financials
- Not Disclosed – The financial terms of the acquisition of SensID by Microbiologics have not been disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Microbiologics | Acquirer | Company | A global biotechnology company specializing in reference materials for infectious diseases and contract research services. |
| SensID | Target | Company | A provider of reference materials and quality controls with a focus on molecular diagnostics for oncology and precision medicine. |
| Granite Partners | Supporting PE Firm | Company | A private investment and holding company based in Saint Cloud, Minnesota, providing support for the acquisition. |
| Kristen Knox | CEO | Person | CEO of Microbiologics, expressing the strategic importance of the acquisition. |
| Björn Nowack | CEO | Person | CEO of SensID, discussing the aligned mission and benefits of the acquisition. |
| Lathrop GPM | Legal Advisor | Other Company | Provided legal representation for the acquisition. |
| HEUSSEN | Legal Advisor | Other Company | Provided legal representation for the acquisition. |
| CliftonLarsonAllen | Financial Advisor | Other Company | Provided financial advice for the acquisition deal. |
| JP Morgan Chase Bank, N.A. | Financier | Other Company | One of the financial institutions providing funding for the acquisition. |
| Bell Capital Finance | Financier | Other Company | Another financial institution providing funding for the acquisition. |